Enteric encapsulation of ancrod for oral administration
AssigneeRobert L. Letcher
InventorsRobert L. Letcher, Jeffrey W. Williams
Life of this patent
Estimating the term…
Abstract
Disclosed is a pharmaceutically effective agent and method of use, comprising ancrod which has been incubated with neuraminidase. The neuraminidase-treated ancrod (NTA) can be substituted for ancrod in ancrod therapy, when immunological resistance to the latter has become manifest. Conversely, NTA can be administered initially, and ancrod substituted therefor after NTA resistance becomes manifest. In a second embodiment, the efficacy of ancrod treatment is improved by enterically coated oral administration of native ancrod.
Claims20
A method of treating vascular disease in a mammal in need of such treatment which comprises:
- orally administering to said mammal an effective amount of enterically coated ancrod.
A biologically effective agent comprising:
- ancrod in an enterically coated oral dosage form.
A method of lysing fibrinogen comprising:
- lysing said fibrinogen with a biologically effective amount of ancrod administered enterically coated orally, to lyse said fibrinogen.
Dependencies are inferred from the claim text.